Surgery Partners sees FY26 revenue $3.35B-$3.45B, consensus $3.56B

Sees FY26 adjusted EBITDA at least $530M. Dave Doherty, CFO, commented, “Our fourth quarter results reflect a degree of margin pressure, which impacted our full-year performance. Looking at 2026, we have taken a measured approach to our guidance as we navigate the near-term operating environment, drive operational improvements across the business, and execute on our core growth pillars to deliver long-term shareholder value. We are confident in our path towards returning to the consistent growth that we know our platform is capable of, supported by strong fundamentals, improving free cash flow, reducing leverage, and executing on our portfolio optimization strategy.”